Skip to main content

Table 4 DFS Multivariate Analysis

From: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation

Outcome Hazard Ratio (95% CI) P-value
NLR
 < 4 ref 0.14
 ≥ 4 1.19 (0.95–1.50)  
PLR
 < 150 ref 0.71
 ≥ 150 0.96 (0.76–1.21)  
Pre-treatment CEA
 < 5 ng/ml ref < 0.01
 ≥ 5 ng/ml 1.66 (1.34–2.05)  
 Unknown 1.85 (1.37–2.51)
Clinical stage 0.01
 II ref  
 III 1.30 (1.02–1.65)
 Unknown 2.46 (1.24–4.90)
Hemoglobin 0.99 (0.99–1.00) 0.02
  1. CEA Carcinoembryonic antigen, DFS Disease-free survival, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio